-
1
-
-
20144379162
-
Endogenous inhibitors of angiogenesis
-
Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65(10): 3967-3979.
-
(2005)
Cancer Res
, vol.65
, Issue.10
, pp. 3967-3979
-
-
Nyberg, P.1
Xie, L.2
Kalluri, R.3
-
2
-
-
0037360164
-
Thrombospondins 1 and 2 function as inhibitors of angiogenesis
-
Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003; 22(1): 63-71.
-
(2003)
Matrix Biol
, vol.22
, Issue.1
, pp. 63-71
-
-
Armstrong, L.C.1
Bornstein, P.2
-
3
-
-
0035940429
-
Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor
-
Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001; 98(22): 12485-12490.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.22
, pp. 12485-12490
-
-
Rodriguez-manzaneque, J.C.1
Lane, T.F.2
Ortega, M.A.3
Hynes, R.O.4
Lawler, J.5
Iruela-arispe, M.L.6
-
4
-
-
0037079243
-
Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice
-
Hawighorst T, Oura H, Streit M, Janes L, Nguyen L, Brown LF, Oliver G, Jackson DG, Detmar M. Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 2002; 21(52): 7945-7956.
-
(2002)
Oncogene
, vol.21
, Issue.52
, pp. 7945-7956
-
-
Hawighorst, T.1
Oura, H.2
Streit, M.3
Janes, L.4
Nguyen, L.5
Brown, L.F.6
Oliver, G.7
Jackson, D.G.8
Detmar, M.9
-
6
-
-
0041785511
-
Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1
-
Volpert OV, Alani RM. Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. Cancer Cell 2003; 3(3): 199-200.
-
(2003)
Cancer Cell
, vol.3
, Issue.3
, pp. 199-200
-
-
Volpert, O.V.1
Alani, R.M.2
-
7
-
-
0032552020
-
p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma
-
Holmgren L, Jackson G, Arbiser J. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 1998; 17(7): 819-824.
-
(1998)
Oncogene
, vol.17
, Issue.7
, pp. 819-824
-
-
Holmgren, L.1
Jackson, G.2
Arbiser, J.3
-
8
-
-
0028609624
-
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
-
Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-6511.
-
(1994)
Cancer Res
, vol.54
, pp. 6504-6511
-
-
Weinstat-saslow, D.L.1
Zabrenetzky, V.S.2
VanHoutte, K.3
Frazier, W.A.4
Roberts, D.D.5
Steeg, P.S.6
-
9
-
-
33845680615
-
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis
-
Almog N, Henke V, Flores L, Hlatky L, Kung AL, Wright RD, Berger R, Hutchinson L, Naumov GN, Bender E, Akslen LA, Achilles EG, Folkman J. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006; 20(7): 947-949.
-
(2006)
FASEB J
, vol.20
, Issue.7
, pp. 947-949
-
-
Almog, N.1
Henke, V.2
Flores, L.3
Hlatky, L.4
Kung, A.L.5
Wright, R.D.6
Berger, R.7
Hutchinson, L.8
Naumov, G.N.9
Bender, E.10
Akslen, L.A.11
Achilles, E.G.12
Folkman, J.13
-
10
-
-
0036168401
-
Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma
-
Kragh M, Quistorff B, Tenan M, Van Meir EG, Kristjansen PE. Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma. Cancer Res 2002; 62(4): 1191-1195.
-
(2002)
Cancer Res
, vol.62
, Issue.4
, pp. 1191-1195
-
-
Kragh, M.1
Quistorff, B.2
Tenan, M.3
Meir, E.G.V.4
Kristjansen, P.E.5
-
11
-
-
0032770860
-
Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
-
Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, Lawler J, Detmar M. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999; 155(2): 441-452.
-
(1999)
Am J Pathol
, vol.155
, Issue.2
, pp. 441-452
-
-
Streit, M.1
Velasco, P.2
Brown, L.F.3
Skobe, M.4
Richard, L.5
Riccardi, L.6
Lawler, J.7
Detmar, M.8
-
12
-
-
0025147371
-
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
-
Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc.Natl.Acad.Sci.USA 1990; 87: 6624-6628.
-
(1990)
Proc.Natl.Acad.Sci.USA
, vol.87
, pp. 6624-6628
-
-
Good, D.J.1
Polverini, P.J.2
Rastinejad, F.3
Beau, M.M.L.4
Lemons, R.S.5
Frazier, W.A.6
Bouck, N.P.7
-
13
-
-
0025370524
-
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor
-
Taraboletti G, Roberts D, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990; 111(2): 765-772.
-
(1990)
J Cell Biol
, vol.111
, Issue.2
, pp. 765-772
-
-
Taraboletti, G.1
Roberts, D.2
Liotta, L.A.3
Giavazzi, R.4
-
15
-
-
0028157338
-
Matrix-bound thrombospondin promotes angiogenesis in vitro
-
Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994; 124: 183-193.
-
(1994)
J Cell Biol
, vol.124
, pp. 183-193
-
-
Nicosia, R.F.1
Tuszynski, G.P.2
-
16
-
-
0027745333
-
Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide
-
BenEzra D, Griffin BW, Maftzir G, Aharonov O. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Ophtalmol Vis Sci 1993; 34: 3601-3608.
-
(1993)
Invest Ophtalmol Vis Sci
, vol.34
, pp. 3601-3608
-
-
BenEzra, D.1
Griffin, B.W.2
Maftzir, G.3
Aharonov, O.4
-
17
-
-
0033813281
-
The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells
-
Taraboletti G, Morbidelli L, Donnini S, Parenti A, Granger HJ, Giavazzi R, Ziche M. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. Faseb J 2000; 14(12): 1674-1676.
-
(2000)
Faseb J
, vol.14
, Issue.12
, pp. 1674-1676
-
-
Taraboletti, G.1
Morbidelli, L.2
Donnini, S.3
Parenti, A.4
Granger, H.J.5
Giavazzi, R.6
Ziche, M.7
-
18
-
-
0034492232
-
Cell contactdependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1
-
Chandrasekaran L, He CZ, Al-Barazi H, Krutzsch HC, Iruela-Arispe ML, Roberts DD. Cell contactdependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell 2000; 11(9): 2885-2900.
-
(2000)
Mol Biol Cell
, vol.11
, Issue.9
, pp. 2885-2900
-
-
Chandrasekaran, L.1
He, C.Z.2
Al-barazi, H.3
Krutzsch, H.C.4
Iruela-arispe, M.L.5
Roberts, D.D.6
-
19
-
-
1542313880
-
Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo
-
Calzada MJ, Zhou L, Sipes JM, Zhang J, Krutzsch HC, Iruela-Arispe ML, Annis DS, Mosher DF, Roberts DD. Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res 2004; 94(4): 462-470.
-
(2004)
Circ Res
, vol.94
, Issue.4
, pp. 462-470
-
-
Calzada, M.J.1
Zhou, L.2
Sipes, J.M.3
Zhang, J.4
Krutzsch, H.C.5
Iruela-arispe, M.L.6
Annis, D.S.7
Mosher, D.F.8
Roberts, D.D.9
-
20
-
-
0033613226
-
Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats
-
Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999; 100(13): 1423-1431.
-
(1999)
Circulation
, vol.100
, Issue.13
, pp. 1423-1431
-
-
Iruela-arispe, M.L.1
Lombardo, M.2
Krutzsch, H.C.3
Lawler, J.4
Roberts, D.D.5
-
21
-
-
0035280238
-
Integrin-associated protein (CD47) and its ligands
-
Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001; 11(3): 130-135.
-
(2001)
Trends Cell Biol
, vol.11
, Issue.3
, pp. 130-135
-
-
Brown, E.J.1
Frazier, W.A.2
-
22
-
-
14844359865
-
Functional regulation of T lymphocytes by modulatory extracellular matrix proteins
-
Kuznetsova SA, Roberts DD. Functional regulation of T lymphocytes by modulatory extracellular matrix proteins. Int J Biochem Cell Biol 2004; 36(6): 1126-1134.
-
(2004)
Int J Biochem Cell Biol
, vol.36
, Issue.6
, pp. 1126-1134
-
-
Kuznetsova, S.A.1
Roberts, D.D.2
-
24
-
-
0034833822
-
CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism
-
Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108(6): 785-791.
-
(2001)
J Clin Invest
, vol.108
, Issue.6
, pp. 785-791
-
-
Febbraio, M.1
Hajjar, D.P.2
Silverstein, R.L.3
-
25
-
-
0026567377
-
Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro
-
Swerlick RA, Lee KH, Wick TM, Lawley TJ. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992; 148(1): 78-83.
-
(1992)
J Immunol
, vol.148
, Issue.1
, pp. 78-83
-
-
Swerlick, R.A.1
Lee, K.H.2
Wick, T.M.3
Lawley, T.J.4
-
26
-
-
0030833817
-
CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells
-
Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138(3): 707-717.
-
(1997)
J Cell Biol
, vol.138
, Issue.3
, pp. 707-717
-
-
Dawson, D.W.1
Pearce, S.F.2
Zhong, R.3
Silverstein, R.L.4
Frazier, W.A.5
Bouck, N.P.6
-
27
-
-
0032570699
-
Lysosomal integral membrane protein II binds thrombospondin-1. Structure-function homology with the cell adhesion molecule CD36 defines a conserved recognition motif
-
Crombie R, Silverstein R. Lysosomal integral membrane protein II binds thrombospondin-1. Structure-function homology with the cell adhesion molecule CD36 defines a conserved recognition motif. J Biol Chem 1998; 273(9): 4855-4863.
-
(1998)
J Biol Chem
, vol.273
, Issue.9
, pp. 4855-4863
-
-
Crombie, R.1
Silverstein, R.2
-
28
-
-
0031983724
-
Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva
-
Crombie R, Silverstein RL, MacLow C, Pearce SF, Nachman RL, Laurence J. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. J Exp Med 1998; 187(1): 25-35.
-
(1998)
J Exp Med
, vol.187
, Issue.1
, pp. 25-35
-
-
Crombie, R.1
Silverstein, R.L.2
MacLow, C.3
Pearce, S.F.4
Nachman, R.L.5
Laurence, J.6
-
29
-
-
3242772439
-
The thrombospondin type 1 repeat superfamily
-
Tucker RP. The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 2004; 36(6): 969-974.
-
(2004)
Int J Biochem Cell Biol
, vol.36
, Issue.6
, pp. 969-974
-
-
Tucker, R.P.1
-
30
-
-
26444476029
-
Identification of CD36 molecular features required for its in vitro angiostatic activity
-
Primo L, Ferrandi C, Roca C, Marchio S, di Blasio L, Alessio M, Bussolino F. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J 2005; 19(12): 1713-1715.
-
(2005)
FASEB J
, vol.19
, Issue.12
, pp. 1713-1715
-
-
Primo, L.1
Ferrandi, C.2
Roca, C.3
Marchio, S.4
di Blasio, L.5
Alessio, M.6
Bussolino, F.7
-
31
-
-
0342445431
-
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
-
Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6(1): 41-48.
-
(2000)
Nat Med
, vol.6
, Issue.1
, pp. 41-48
-
-
Jimenez, B.1
Volpert, O.V.2
Crawford, S.E.3
Febbraio, M.4
Silverstein, R.L.5
Bouck, N.6
-
32
-
-
33748747969
-
CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1
-
Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006; 281(36): 26069-26080.
-
(2006)
J Biol Chem
, vol.281
, Issue.36
, pp. 26069-26080
-
-
Isenberg, J.S.1
Ridnour, L.A.2
Dimitry, J.3
Frazier, W.A.4
Wink, D.A.5
Roberts, D.D.6
-
33
-
-
0036104828
-
Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor
-
Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8(4): 349-357.
-
(2002)
Nat Med
, vol.8
, Issue.4
, pp. 349-357
-
-
Volpert, O.V.1
Zaichuk, T.2
Zhou, W.3
Reiher, F.4
Ferguson, T.A.5
Stuart, P.M.6
Amin, M.7
Bouck, N.P.8
-
34
-
-
58649096802
-
Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1
-
Rege TA, Stewart J, Jr., Dranka B, Benveniste EN, Silverstein RL, Gladson CL. Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol 2009; 218(1): 94-103.
-
(2009)
J Cell Physiol
, vol.218
, Issue.1
, pp. 94-103
-
-
Rege, T.A.1
Stewart Jr, J.2
Dranka, B.3
Benveniste, E.N.4
Silverstein, R.L.5
Gladson, C.L.6
-
35
-
-
0029862392
-
Thrombospondin modulates alpha v beta 3 function through integrin-associated protein
-
Gao AG, Lindberg FP, Dimitry JM, Brown EJ, Frazier WA. Thrombospondin modulates alpha v beta 3 function through integrin-associated protein. J Cell Biol 1996; 135(2): 533-544.
-
(1996)
J Cell Biol
, vol.135
, Issue.2
, pp. 533-544
-
-
Gao, A.G.1
Lindberg, F.P.2
Dimitry, J.M.3
Brown, E.J.4
Frazier, W.A.5
-
36
-
-
0030032579
-
Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin
-
Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996; 271(1): 21-24.
-
(1996)
J Biol Chem
, vol.271
, Issue.1
, pp. 21-24
-
-
Gao, A.G.1
Lindberg, F.P.2
Finn, M.B.3
Blystone, S.D.4
Brown, E.J.5
Frazier, W.A.6
-
38
-
-
0033230597
-
Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis
-
Kanda S, Shono T, Tomasini-Johansson B, Klint P, Saito Y. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp Cell Res 1999; 252(2): 262-272.
-
(1999)
Exp Cell Res
, vol.252
, Issue.2
, pp. 262-272
-
-
Kanda, S.1
Shono, T.2
Tomasini-johansson, B.3
Klint, P.4
Saito, Y.5
-
39
-
-
48249107523
-
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow
-
Isenberg JS, Hyodo F, Ridnour LA, Shannon CS, Wink DA, Krishna MC, Roberts DD. Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia 2008; 10(8): 886-896.
-
(2008)
Neoplasia
, vol.10
, Issue.8
, pp. 886-896
-
-
Isenberg, J.S.1
Hyodo, F.2
Ridnour, L.A.3
Shannon, C.S.4
Wink, D.A.5
Krishna, M.C.6
Roberts, D.D.7
-
40
-
-
38449103435
-
Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1
-
Nunes SS, Outeiro-Bernstein MA, Juliano L, Vardiero F, Nader HB, Woods A, Legrand C, Morandi V. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1. J Cell Physiol 2008; 214(3): 828-837.
-
(2008)
J Cell Physiol
, vol.214
, Issue.3
, pp. 828-837
-
-
Nunes, S.S.1
Outeiro-bernstein, M.A.2
Juliano, L.3
Vardiero, F.4
Nader, H.B.5
Woods, A.6
Legrand, C.7
Morandi, V.8
-
41
-
-
0042170209
-
Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration
-
Orr AW, Elzie CA, Kucik DF, Murphy-Ullrich JE. Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration. J Cell Sci 2003; 116(Pt 14): 2917-2927.
-
(2003)
J Cell Sci
, vol.116
, Issue.14 PT
, pp. 2917-2927
-
-
Orr, A.W.1
Elzie, C.A.2
Kucik, D.F.3
Murphy-ullrich, J.E.4
-
42
-
-
0029007213
-
Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1
-
Godyna S, Liau G, Popa I, Stefansson S, Argraves WS. Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol 1995; 129(5): 1403-1410.
-
(1995)
J Cell Biol
, vol.129
, Issue.5
, pp. 1403-1410
-
-
Godyna, S.1
Liau, G.2
Popa, I.3
Stefansson, S.4
Argraves, W.S.5
-
43
-
-
39449127385
-
Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells
-
Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 2008; 19(2): 563-571.
-
(2008)
Mol Biol Cell
, vol.19
, Issue.2
, pp. 563-571
-
-
Oganesian, A.1
Armstrong, L.C.2
Migliorini, M.M.3
Strickland, D.K.4
Bornstein, P.5
-
44
-
-
33846598411
-
Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1)
-
Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 2007; 210(3): 807-818.
-
(2007)
J Cell Physiol
, vol.210
, Issue.3
, pp. 807-818
-
-
Greenaway, J.1
Lawler, J.2
Moorehead, R.3
Bornstein, P.4
Lamarre, J.5
Petrik, J.6
-
45
-
-
27144541479
-
Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model
-
Fears CY, Grammer JR, Stewart JE, Jr., Annis DS, Mosher DF, Bornstein P, Gladson CL. Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Res 2005; 65(20): 9338-9346.
-
(2005)
Cancer Res
, vol.65
, Issue.20
, pp. 9338-9346
-
-
Fears, C.Y.1
Grammer, J.R.2
Stewart Jr, J.E.3
Annis, D.S.4
Mosher, D.F.5
Bornstein, P.6
Gladson, C.L.7
-
46
-
-
0035896646
-
Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2
-
Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001; 276(11): 8403-8408.
-
(2001)
J Biol Chem
, vol.276
, Issue.11
, pp. 8403-8408
-
-
Yang, Z.1
Strickland, D.K.2
Bornstein, P.3
-
47
-
-
0033588298
-
Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1
-
Krutzsch HC, Choe BJ, Sipes JM, Guo N, Roberts DD. Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. J Biol Chem 1999; 274(34): 24080-24086.
-
(1999)
J Biol Chem
, vol.274
, Issue.34
, pp. 24080-24086
-
-
Krutzsch, H.C.1
Choe, B.J.2
Sipes, J.M.3
Guo, N.4
Roberts, D.D.5
-
48
-
-
0142103475
-
Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha6beta1 integrin
-
Calzada MJ, Sipes JM, Krutzsch HC, Yurchenco PD, Annis DS, Mosher DF, Roberts DD. Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha6beta1 integrin. J Biol Chem 2003; 278(42): 40679-40687.
-
(2003)
J Biol Chem
, vol.278
, Issue.42
, pp. 40679-40687
-
-
Calzada, M.J.1
Sipes, J.M.2
Krutzsch, H.C.3
Yurchenco, P.D.4
Annis, D.S.5
Mosher, D.F.6
Roberts, D.D.7
-
49
-
-
4744352055
-
Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1
-
Calzada MJ, Annis DS, Zeng B, Marcinkiewicz C, Banas B, Lawler J, Mosher DF, Roberts DD. Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem 2004; 279(40): 41734-41743.
-
(2004)
J Biol Chem
, vol.279
, Issue.40
, pp. 41734-41743
-
-
Calzada, M.J.1
Annis, D.S.2
Zeng, B.3
Marcinkiewicz, C.4
Banas, B.5
Lawler, J.6
Mosher, D.F.7
Roberts, D.D.8
-
50
-
-
13944267041
-
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins
-
Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 2005; 168(4): 643-653.
-
(2005)
J Cell Biol
, vol.168
, Issue.4
, pp. 643-653
-
-
Short, S.M.1
Derrien, A.2
Narsimhan, R.P.3
Lawler, J.4
Ingber, D.E.5
Zetter, B.R.6
-
51
-
-
34248376549
-
Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis
-
Staniszewska I, Zaveri S, Del Valle L, Oliva I, Rothman VL, Croul SE, Roberts DD, Mosher DF, Tuszynski GP, Marcinkiewicz C. Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res 2007; 100(9): 1308-1316.
-
(2007)
Circ Res
, vol.100
, Issue.9
, pp. 1308-1316
-
-
Staniszewska, I.1
Zaveri, S.2
Valle, L.D.3
Oliva, I.4
Rothman, V.L.5
Croul, S.E.6
Roberts, D.D.7
Mosher, D.F.8
Tuszynski, G.P.9
Marcinkiewicz, C.10
-
52
-
-
0024263694
-
Cell attachment to thrombospondin: the role of Arg-Gly-Asp, calcium, and integrin receptors
-
Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombospondin: the role of Arg-Gly-Asp, calcium, and integrin receptors. J Cell Biol 1988; 107: 2351-2361.
-
(1988)
J Cell Biol
, vol.107
, pp. 2351-2361
-
-
Lawler, J.1
Weinstein, R.2
Hynes, R.O.3
-
54
-
-
53449086315
-
Integrins: the keys to unlocking angiogenesis
-
Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE. Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 2008; 28(10): 1703-1713.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
, Issue.10
, pp. 1703-1713
-
-
Silva, R.1
D'Amico, G.2
Hodivala-dilke, K.M.3
Reynolds, L.E.4
-
55
-
-
33746802333
-
Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey
-
Rusnati M, Presta M. Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey. Endothelium 2006; 13(2): 93-111.
-
(2006)
Endothelium
, vol.13
, Issue.2
, pp. 93-111
-
-
Rusnati, M.1
Presta, M.2
-
57
-
-
0029764443
-
Scatter factor binds to thrombospondin and other extracellular matrix components
-
Lamszus K, Joseph A, Jin L, Yao Y, Chowdhury S, Fuchs A, Polverini PJ, Goldberg ID, Rosen EM. Scatter factor binds to thrombospondin and other extracellular matrix components. Am J Pathol 1996; 149(3): 805-819.
-
(1996)
Am J Pathol
, vol.149
, Issue.3
, pp. 805-819
-
-
Lamszus, K.1
Joseph, A.2
Jin, L.3
Yao, Y.4
Chowdhury, S.5
Fuchs, A.6
Polverini, P.J.7
Goldberg, I.D.8
Rosen, E.M.9
-
58
-
-
0030964285
-
The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor
-
Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, Presta M, Giavazzi R. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 1997; 8(4): 471-479.
-
(1997)
Cell Growth Differ
, vol.8
, Issue.4
, pp. 471-479
-
-
Taraboletti, G.1
Belotti, D.2
Borsotti, P.3
Vergani, V.4
Rusnati, M.5
Presta, M.6
Giavazzi, R.7
-
59
-
-
0345167898
-
Thrombospondin 1 as a scavenger for matrixassociated fibroblast growth factor 2
-
Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, Taraboletti G. Thrombospondin 1 as a scavenger for matrixassociated fibroblast growth factor 2. Blood 2003; 102(13): 4399-4406.
-
(2003)
Blood
, vol.102
, Issue.13
, pp. 4399-4406
-
-
Margosio, B.1
Marchetti, D.2
Vergani, V.3
Giavazzi, R.4
Rusnati, M.5
Presta, M.6
Taraboletti, G.7
-
60
-
-
39649111093
-
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain
-
Margosio B, Rusnati M, Bonezzi K, Cordes BL, Annis DS, Urbinati C, Giavazzi R, Presta M, Ribatti D, Mosher DF, Taraboletti G. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008; 40(4): 700-709.
-
(2008)
Int J Biochem Cell Biol
, vol.40
, Issue.4
, pp. 700-709
-
-
Margosio, B.1
Rusnati, M.2
Bonezzi, K.3
Cordes, B.L.4
Annis, D.S.5
Urbinati, C.6
Giavazzi, R.7
Presta, M.8
Ribatti, D.9
Mosher, D.F.10
Taraboletti, G.11
-
61
-
-
0033820634
-
Thrombospondin-1/HIV-1 tat protein interaction: modulation of the biological activity of extracellular Tat
-
Rusnati M, Taraboletti G, Urbinati C, Tulipano G, Giuliani R, Molinari-Tosatti MP, Sennino B, Giacca M, Tyagi M, Albini A, Noonan D, Giavazzi R, Presta M. Thrombospondin-1/HIV-1 tat protein interaction: modulation of the biological activity of extracellular Tat. Faseb J 2000; 14(13): 1917-1930.
-
(2000)
Faseb J
, vol.14
, Issue.13
, pp. 1917-1930
-
-
Rusnati, M.1
Taraboletti, G.2
Urbinati, C.3
Tulipano, G.4
Giuliani, R.5
Molinari-tosatti, M.P.6
Sennino, B.7
Giacca, M.8
Tyagi, M.9
Albini, A.10
Noonan, D.11
Giavazzi, R.12
Presta, M.13
-
62
-
-
0009849965
-
Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis
-
Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999; 3: 147-158.
-
(1999)
Angiogenesis
, vol.3
, pp. 147-158
-
-
Gupta, K.1
Gupta, P.2
Wild, R.3
Ramakrishnan, S.4
Hebbel, R.P.5
-
63
-
-
0036481769
-
Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis
-
Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, Okada Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Faseb J 2002; 16(2): 219-221.
-
(2002)
Faseb J
, vol.16
, Issue.2
, pp. 219-221
-
-
Inoki, I.1
Shiomi, T.2
Hashimoto, G.3
Enomoto, H.4
Nakamura, H.5
Makino, K.6
Ikeda, E.7
Takata, S.8
Kobayashi, K.9
Okada, Y.10
-
64
-
-
0028625495
-
Thrombospondin 1 as an enzyme inhibitor
-
Hogg PJ. Thrombospondin 1 as an enzyme inhibitor. Thrombosis and Haemostasis 1994; 72: 787-792.
-
(1994)
Thrombosis and Haemostasis
, vol.72
, pp. 787-792
-
-
Hogg, P.J.1
-
66
-
-
0031572311
-
Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells
-
Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 1997; 235(2): 403-412.
-
(1997)
Exp Cell Res
, vol.235
, Issue.2
, pp. 403-412
-
-
Qian, X.1
Wang, T.N.2
Rothman, V.L.3
Nicosia, R.F.4
Tuszynski, G.P.5
-
67
-
-
0034644748
-
Thrombospondin type 1 repeats interact with matrix metalloproteinase 2
-
Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 2000; 275(41): 32167-32173.
-
(2000)
Regulation of metalloproteinase activity. J Biol Chem
, vol.275
, Issue.41
, pp. 32167-32173
-
-
Bein, K.1
Simons, M.2
-
68
-
-
0028902002
-
Regulation of transforming growth factor-b activation by discrete sequences of thrombospondin 1
-
Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE. Regulation of transforming growth factor-b activation by discrete sequences of thrombospondin 1. J Biol Chem 1995; 270: 7304-7310.
-
(1995)
J Biol Chem
, vol.270
, pp. 7304-7310
-
-
Schultz-cherry, S.1
Chen, H.2
Mosher, D.F.3
Misenheimer, T.M.4
Krutzsch, H.C.5
Roberts, D.D.6
Murphy-ullrich, J.E.7
-
69
-
-
9144259278
-
The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex
-
Young GD, Murphy-Ullrich JE. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem 2004; 279(46): 47633-47642.
-
(2004)
J Biol Chem
, vol.279
, Issue.46
, pp. 47633-47642
-
-
Young, G.D.1
Murphy-ullrich, J.E.2
-
70
-
-
58849135842
-
The effect of thrombospondin-1 on breast cancer metastasis
-
Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat 2009; 114(1): 85-96.
-
(2009)
Breast Cancer Res Treat
, vol.114
, Issue.1
, pp. 85-96
-
-
Yee, K.O.1
Connolly, C.M.2
Duquette, M.3
Kazerounian, S.4
Washington, R.5
Lawler, J.6
-
71
-
-
0034704174
-
Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain
-
Borges E, Jan Y, Ruoslahti E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 2000; 275(51): 39867-39873.
-
(2000)
J Biol Chem
, vol.275
, Issue.51
, pp. 39867-39873
-
-
Borges, E.1
Jan, Y.2
Ruoslahti, E.3
-
72
-
-
52949084316
-
A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells
-
Karagiannis ED, Popel AS. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci U S A 2008; 105(37): 13775-13780.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.37
, pp. 13775-13780
-
-
Karagiannis, E.D.1
Popel, A.S.2
-
73
-
-
16844380395
-
Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model
-
Zhang X, Galardi E, Duquette M, Delic M, Lawler J, Parangi S. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 2005; 11(6): 2337-2344.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.6
, pp. 2337-2344
-
-
Zhang, X.1
Galardi, E.2
Duquette, M.3
Delic, M.4
Lawler, J.5
Parangi, S.6
-
74
-
-
33845674173
-
Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model
-
Zhang X, Connolly C, Duquette M, Lawler J, Parangi S. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett 2007; 247(1): 143-149.
-
(2007)
Cancer Lett
, vol.247
, Issue.1
, pp. 143-149
-
-
Zhang, X.1
Connolly, C.2
Duquette, M.3
Lawler, J.4
Parangi, S.5
-
75
-
-
0033027727
-
Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat
-
Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 1999; 55(2): 332-338.
-
(1999)
Mol Pharmacol
, vol.55
, Issue.2
, pp. 332-338
-
-
Dawson, D.W.1
Volpert, O.V.2
Pearce, S.F.3
Schneider, A.J.4
Silverstein, R.L.5
Henkin, J.6
Bouck, N.P.7
-
76
-
-
0026507226
-
Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding
-
Asch AS, Silbiger S, Heimer E, Nachman RL. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem Biophys Res Commun 1992; 182(3): 1208-1217.
-
(1992)
Biochem Biophys Res Commun
, vol.182
, Issue.3
, pp. 1208-1217
-
-
Asch, A.S.1
Silbiger, S.2
Heimer, E.3
Nachman, R.L.4
-
77
-
-
0037191047
-
Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication
-
Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol 2002; 159(2): 373-782.
-
(2002)
J Cell Biol
, vol.159
, Issue.2
, pp. 373-782
-
-
Tan, K.1
Duquette, M.2
Liu, J.H.3
Dong, Y.4
Zhang, R.5
Joachimiak, A.6
Lawler, J.7
Wang, J.H.8
-
78
-
-
0027449459
-
Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin
-
Vogel T, Guo N, Krutzsch HC, Blake DA, Hartman J, Mendelovitz S, Panet A, Roberts DD. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 1993; 53: 74-84.
-
(1993)
J Cell Biochem
, vol.53
, pp. 74-84
-
-
Vogel, T.1
Guo, N.2
Krutzsch, H.C.3
Blake, D.A.4
Hartman, J.5
Mendelovitz, S.6
Panet, A.7
Roberts, D.D.8
-
79
-
-
0030904193
-
Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells
-
Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997; 57(9): 1735-1742.
-
(1997)
Cancer Res
, vol.57
, Issue.9
, pp. 1735-1742
-
-
Guo, N.1
Krutzsch, H.C.2
Inman, J.K.3
Roberts, D.D.4
-
80
-
-
0030874871
-
Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1
-
Guo NH, Krutzsch HC, Inman JK, Shannon CS, Roberts DD. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res 1997; 50(3): 210-21.
-
(1997)
J Pept Res
, vol.50
, Issue.3
, pp. 210-221
-
-
Guo, N.H.1
Krutzsch, H.C.2
Inman, J.K.3
Shannon, C.S.4
Roberts, D.D.5
-
81
-
-
0027290714
-
Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity
-
Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993; 122(2): 497-511.
-
(1993)
J Cell Biol
, vol.122
, Issue.2
, pp. 497-511
-
-
Tolsma, S.S.1
Volpert, O.V.2
Good, D.J.3
Frazier, W.A.4
Polverini, P.J.5
Bouck, N.6
-
82
-
-
4444313333
-
Functions of the conserved thrombospondin carboxy-terminal cassette in cellextracellular matrix interactions and signaling
-
Adams JC. Functions of the conserved thrombospondin carboxy-terminal cassette in cellextracellular matrix interactions and signaling. Int J Biochem Cell Biol 2004; 36(6): 1102-1114.
-
(2004)
Int J Biochem Cell Biol
, vol.36
, Issue.6
, pp. 1102-1114
-
-
Adams, J.C.1
-
83
-
-
1942535754
-
Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats
-
Kvansakul M, Adams JC, Hohenester E. Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. Embo J 2004; 23(6): 1223-1233.
-
(2004)
Embo J
, vol.23
, Issue.6
, pp. 1223-1233
-
-
Kvansakul, M.1
Adams, J.C.2
Hohenester, E.3
-
84
-
-
0033818524
-
Residues F16-G33 and A784-N823 within platelet thrombospondin-1 play a major role in binding human neutrophils: evaluation by two novel binding assays
-
Majluf-Cruz A, Manns JM, Uknis AB, Yang X, Colman RW, Harris RB, Frazier W, Lawler J, DeLa Cadena RA. Residues F16-G33 and A784-N823 within platelet thrombospondin-1 play a major role in binding human neutrophils: evaluation by two novel binding assays. J Lab Clin Med 2000; 136(4): 292-302.
-
(2000)
J Lab Clin Med
, vol.136
, Issue.4
, pp. 292-302
-
-
Majluf-cruz, A.1
Manns, J.M.2
Uknis, A.B.3
Yang, X.4
Colman, R.W.5
Harris, R.B.6
Frazier, W.7
Lawler, J.8
DeLa Cadena, R.A.9
-
85
-
-
0038494616
-
Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit sickle cell adhesion
-
Watkins NA, Du LM, Scott JP, Ouwehand WH, Hillery CA. Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit sickle cell adhesion. Blood 2003; 102(2): 718-724.
-
(2003)
Blood
, vol.102
, Issue.2
, pp. 718-724
-
-
Watkins, N.A.1
Du, L.M.2
Scott, J.P.3
Ouwehand, W.H.4
Hillery, C.A.5
-
86
-
-
27144455173
-
Structure of the calcium-rich signature domain of human thrombospondin-2
-
Carlson CB, Bernstein DA, Annis DS, Misenheimer TM, Hannah BL, Mosher DF, Keck JL. Structure of the calcium-rich signature domain of human thrombospondin-2. Nat Struct Mol Biol 2005; 12(10): 910-914.
-
(2005)
Nat Struct Mol Biol
, vol.12
, Issue.10
, pp. 910-914
-
-
Carlson, C.B.1
Bernstein, D.A.2
Annis, D.S.3
Misenheimer, T.M.4
Hannah, B.L.5
Mosher, D.F.6
Keck, J.L.7
-
87
-
-
34447291351
-
Developing antiangiogenic peptide drugs for angiogenesis-related diseases
-
Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 2007; 13(20): 2074-2086.
-
(2007)
Curr Pharm Des
, vol.13
, Issue.20
, pp. 2074-2086
-
-
Sulochana, K.N.1
Ge, R.2
-
88
-
-
34249666657
-
Anti-angiogenic peptides identified in thrombospondin type I domains
-
Karagiannis ED, Popel AS. Anti-angiogenic peptides identified in thrombospondin type I domains. Biochem Biophys Res Commun 2007; 359(1): 63-69.
-
(2007)
Biochem Biophys Res Commun
, vol.359
, Issue.1
, pp. 63-69
-
-
Karagiannis, E.D.1
Popel, A.S.2
-
89
-
-
34748905971
-
Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells
-
Karagiannis ED, Popel AS. Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells. Int J Biochem Cell Biol 2007; 39(12): 2314-2323.
-
(2007)
Int J Biochem Cell Biol
, vol.39
, Issue.12
, pp. 2314-2323
-
-
Karagiannis, E.D.1
Popel, A.S.2
-
90
-
-
0035281805
-
Anginex, a designed peptide that inhibits angiogenesis
-
Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, Mayo KH. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001; 354(Pt 2): 233-242.
-
(2001)
Biochem J
, vol.354
, Issue.2 PT
, pp. 233-242
-
-
Griffioen, A.W.1
Van Der Schaft, D.W.2
Barendsz-janson, A.F.3
Cox, A.4
Boudier, H.A.S.5
Hillen, H.F.6
Mayo, K.H.7
-
91
-
-
0037051655
-
Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics
-
Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002; 98(5): 682-689.
-
(2002)
Int J Cancer
, vol.98
, Issue.5
, pp. 682-689
-
-
Reiher, F.K.1
Volpert, O.V.2
Jimenez, B.3
Crawford, S.E.4
Dinney, C.P.5
Henkin, J.6
Haviv, F.7
Bouck, N.P.8
Campbell, S.C.9
-
92
-
-
20944443196
-
Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities
-
Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, Marsh KC, Surber BW, Uchic JT, Ferrero J, Wang YC, Leal J, Record RD, Hodde J, Badylak SF, Lesniewski RR, Henkin J. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005; 48(8): 2838-2346.
-
(2005)
J Med Chem
, vol.48
, Issue.8
, pp. 2838-2346
-
-
Haviv, F.1
Bradley, M.F.2
Kalvin, D.M.3
Schneider, A.J.4
Davidson, D.J.5
Majest, S.M.6
McKay, L.M.7
Haskell, C.J.8
Bell, R.L.9
Nguyen, B.10
Marsh, K.C.11
Surber, B.W.12
Uchic, J.T.13
Ferrero, J.14
Wang, Y.C.15
Leal, J.16
Record, R.D.17
Hodde, J.18
Badylak, S.F.19
Lesniewski, R.R.20
Henkin, J.21
more..
-
93
-
-
34548219477
-
ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis
-
Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE, Jr., Gladson CL. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 2007; 6(3): 454-462.
-
(2007)
Cancer Biol Ther
, vol.6
, Issue.3
, pp. 454-462
-
-
Anderson, J.C.1
Grammer, J.R.2
Wang, W.3
Nabors, L.B.4
Henkin, J.5
Stewart Jr, J.E.6
Gladson, C.L.7
-
94
-
-
20044376571
-
In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment
-
Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S, Volpert OV, Redondo JM. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 2005; 12(6): 649-658.
-
(2005)
Cell Death Differ
, vol.12
, Issue.6
, pp. 649-658
-
-
Quesada, A.J.1
Nelius, T.2
Yap, R.3
Zaichuk, T.A.4
Alfranca, A.5
Filleur, S.6
Volpert, O.V.7
Redondo, J.M.8
-
95
-
-
38649110737
-
Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells
-
Isenberg JS, Yu C, Roberts DD. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol 2008; 75(4): 875-882.
-
(2008)
Biochem Pharmacol
, vol.75
, Issue.4
, pp. 875-882
-
-
Isenberg, J.S.1
Yu, C.2
Roberts, D.D.3
-
96
-
-
0042967959
-
Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors
-
Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 2003; 22(16): 4091-4102.
-
(2003)
EMBO J
, vol.22
, Issue.16
, pp. 4091-4102
-
-
Viloria-petit, A.1
Miquerol, L.2
Yu, J.L.3
Gertsenstein, M.4
Sheehan, C.5
May, L.6
Henkin, J.7
Lobe, C.8
Nagy, A.9
Kerbel, R.S.10
Rak, J.11
-
97
-
-
58149521990
-
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer
-
Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 2009; 8(1): 64-74.
-
(2009)
Mol Cancer Ther
, vol.8
, Issue.1
, pp. 64-74
-
-
Greenaway, J.1
Henkin, J.2
Lawler, J.3
Moorehead, R.4
Petrik, J.5
-
98
-
-
25144488561
-
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy
-
Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005; 11(18): 6678-6685.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.18
, pp. 6678-6685
-
-
Yap, R.1
Veliceasa, D.2
Emmenegger, U.3
Kerbel, R.S.4
McKay, L.M.5
Henkin, J.6
Volpert, O.V.7
-
99
-
-
33847701595
-
Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma
-
Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007; 67(4): 1716-1724.
-
(2007)
Cancer Res
, vol.67
, Issue.4
, pp. 1716-1724
-
-
Yang, Q.1
Tian, Y.2
Liu, S.3
Zeine, R.4
Chlenski, A.5
Salwen, H.R.6
Henkin, J.7
Cohn, S.L.8
-
100
-
-
33846228382
-
Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers
-
Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006; 12(24): 7444-7455.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.24
, pp. 7444-7455
-
-
Rusk, A.1
McKeegan, E.2
Haviv, F.3
Majest, S.4
Henkin, J.5
Khanna, C.6
-
101
-
-
33846221453
-
Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma
-
Rusk A, Cozzi E, Stebbins M, Vail D, Graham J, Valli V, Henkin J, Sharpee R, Khanna C. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 2006; 12(24): 7456-7464.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.24
, pp. 7456-7464
-
-
Rusk, A.1
Cozzi, E.2
Stebbins, M.3
Vail, D.4
Graham, J.5
Valli, V.6
Henkin, J.7
Sharpee, R.8
Khanna, C.9
-
102
-
-
24644508961
-
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer
-
Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005; 23(22): 5188-5197.
-
(2005)
J Clin Oncol
, vol.23
, Issue.22
, pp. 5188-5197
-
-
Hoekstra, R.1
de Vos, F.Y.2
Eskens, F.A.3
Gietema, J.A.4
Van Der Gaast, A.5
Groen, H.J.6
Knight, R.A.7
Carr, R.A.8
Humerickhouse, R.A.9
Verweij, J.10
de Vries, E.G.11
-
103
-
-
36749060830
-
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma
-
Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007; 13(22 Pt 1): 6689-6695.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.22 PT
, pp. 6689-6695
-
-
Ebbinghaus, S.1
Hussain, M.2
Tannir, N.3
Gordon, M.4
Desai, A.A.5
Knight, R.A.6
Humerickhouse, R.A.7
Qian, J.8
Gordon, G.B.9
Figlin, R.10
-
104
-
-
57149111052
-
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma
-
Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, Carr RA, Gordon GB, Demetri GD. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008; 26(34): 5583-5588.
-
(2008)
J Clin Oncol
, vol.26
, Issue.34
, pp. 5583-5588
-
-
Baker, L.H.1
Rowinsky, E.K.2
Mendelson, D.3
Humerickhouse, R.A.4
Knight, R.A.5
Qian, J.6
Carr, R.A.7
Gordon, G.B.8
Demetri, G.D.9
-
105
-
-
34249990658
-
A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
-
Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007; 30(3): 303-309.
-
(2007)
Am J Clin Oncol
, vol.30
, Issue.3
, pp. 303-309
-
-
Markovic, S.N.1
Suman, V.J.2
Rao, R.A.3
Ingle, J.N.4
Kaur, J.S.5
Erickson, L.A.6
Pitot, H.C.7
Croghan, G.A.8
McWilliams, R.R.9
Merchan, J.10
Kottschade, L.A.11
Nevala, W.K.12
Uhl, C.B.13
Allred, J.14
Creagan, E.T.15
-
106
-
-
33747883001
-
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors
-
Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ, Loos WJ, Knight RA, Carr RA, Humerickhouse RA, Eskens FA. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 2006; 17(8): 1320-1327.
-
(2006)
Ann Oncol
, vol.17
, Issue.8
, pp. 1320-1327
-
-
Gietema, J.A.1
Hoekstra, R.2
de Vos, F.Y.3
Uges, D.R.4
Van Der Gaast, A.5
Groen, H.J.6
Loos, W.J.7
Knight, R.A.8
Carr, R.A.9
Humerickhouse, R.A.10
Eskens, F.A.11
-
107
-
-
32444431721
-
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination
-
Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R, Carr RA, Humerickhouse R, Verweij J, Gietema JA. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 2006; 42(4): 467-472.
-
(2006)
Eur J Cancer
, vol.42
, Issue.4
, pp. 467-472
-
-
Hoekstra, R.1
de Vos, F.Y.2
Eskens, F.A.3
de Vries, E.G.4
Uges, D.R.5
Knight, R.6
Carr, R.A.7
Humerickhouse, R.8
Verweij, J.9
Gietema, J.A.10
-
108
-
-
84884455248
-
CVX.045: a novel thrombospondin-1 (TSP-1) mimetic CovX-Body(TM) that potentiates chemotherapy and targeted therapy in preclinical xenograft models
-
99th Annual meeting of the American Association for Cancer Research, San Diego, CA, AACR: San Diego, CA, p Abstract nr
-
Pirie-Shepherd SR, Leedom TA, Do J, Huang H, Lingna L, Lai J, Johnson K, Osothprarop T, Rizzo JD, Doppalapudi VR, Lappe RW, Bradshaw C, Roberts S, Levin NJ, Woodnutt G CVX.045: a novel thrombospondin-1 (TSP-1) mimetic CovX-Body(TM) that potentiates chemotherapy and targeted therapy in preclinical xenograft models, 99th Annual meeting of the American Association for Cancer Research, San Diego, CA, AACR: San Diego, CA, 2008; p Abstract nr 1114.
-
(2008)
, pp. 1114
-
-
Pirie-shepherd, S.R.1
Leedom, T.A.2
Do, J.3
Huang, H.4
Lingna, L.5
Lai, J.6
Johnson, K.7
Osothprarop, T.8
Rizzo, J.D.9
Doppalapudi, V.R.10
Lappe, R.W.11
Bradshaw, C.12
Roberts, S.13
Levin, N.J.14
Woodnutt, G.15
-
109
-
-
80255131628
-
CVX-045: a novel thrombospondin-1 (TSP-1) mimetic CovX-Body that potentiates chemotherapy in preclinical colon cancer models
-
Levin NJ, Leedom TA, Doppalapudi VR, Li L, Lai J, Johnson K, Rizzo JD, Lappe RW, Bradshaw CW, Woodnutt G. CVX-045: a novel thrombospondin-1 (TSP-1) mimetic CovX-Body that potentiates chemotherapy in preclinical colon cancer models. J Clin Oncol 2007; 25: 14011.
-
(2007)
J Clin Oncol
, vol.25
, pp. 14011
-
-
Levin, N.J.1
Leedom, T.A.2
Doppalapudi, V.R.3
Li, L.4
Lai, J.5
Johnson, K.6
Rizzo, J.D.7
Lappe, R.W.8
Bradshaw, C.W.9
Woodnutt, G.10
-
110
-
-
54549095308
-
Firstin-human dose escalation safety and pharmacocynetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors
-
Mendelson DS, Dinolfa M, Cohen RB, Rosen LS, Gordon MS, Byrnes B, Bear I, Schoenfeld SL. Firstin-human dose escalation safety and pharmacocynetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors. J Clin Oncol 2008; 26(15S): 3524.
-
(2008)
J Clin Oncol
, vol.26
, Issue.15 S
, pp. 3524
-
-
Mendelson, D.S.1
Dinolfa, M.2
Cohen, R.B.3
Rosen, L.S.4
Gordon, M.S.5
Byrnes, B.6
Bear, I.7
Schoenfeld, S.L.8
-
111
-
-
62549160588
-
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
-
Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting. J Hematol Oncol 2008; 1(1): 20.
-
(2008)
J Hematol Oncol
, vol.1
, Issue.1
, pp. 20
-
-
Molckovsky, A.1
Siu, L.L.2
-
112
-
-
34447129571
-
Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin
-
Zhang X, Xu J, Lawler J, Terwilliger E, Parangi S. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res 2007; 13(13): 3968-3976.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.13
, pp. 3968-3976
-
-
Zhang, X.1
Xu, J.2
Lawler, J.3
Terwilliger, E.4
Parangi, S.5
-
113
-
-
0036531805
-
Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy
-
Streit M, Stephen AE, Hawighorst T, Matsuda K, Lange-Asschenfeldt B, Brown LF, Vacanti JP, Detmar M. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 2002; 62(7): 2004-2012.
-
(2002)
Cancer Res
, vol.62
, Issue.7
, pp. 2004-2012
-
-
Streit, M.1
Stephen, A.E.2
Hawighorst, T.3
Matsuda, K.4
Lange-asschenfeldt, B.5
Brown, L.F.6
Vacanti, J.P.7
Detmar, M.8
-
114
-
-
33646136232
-
Regulation of tumor angiogenesis by thrombospondin-1
-
Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006; 1765(2): 178-188.
-
(2006)
Biochim Biophys Acta
, vol.1765
, Issue.2
, pp. 178-188
-
-
Ren, B.1
Yee, K.O.2
Lawler, J.3
Khosravi-far, R.4
-
115
-
-
0035504921
-
p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis
-
Vikhanskaya F, Bani MR, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, Marabese M, Giavazzi R, Broggini M, Taraboletti G. p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene 2001; 20(50): 7293-7300.
-
(2001)
Oncogene
, vol.20
, Issue.50
, pp. 7293-7300
-
-
Vikhanskaya, F.1
Bani, M.R.2
Borsotti, P.3
Ghilardi, C.4
Ceruti, R.5
Ghisleni, G.6
Marabese, M.7
Giavazzi, R.8
Broggini, M.9
Taraboletti, G.10
-
116
-
-
0028060380
-
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
-
Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265(5178): 1582-1584.
-
(1994)
Science
, vol.265
, Issue.5178
, pp. 1582-1584
-
-
Dameron, K.M.1
Volpert, O.V.2
Tainsky, M.A.3
Bouck, N.4
-
117
-
-
0028672529
-
The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin
-
Dameron KM, Volpert OV, Tainsky MA, Bouck N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994; 59: 483-489.
-
(1994)
Cold Spring Harb Symp Quant Biol
, vol.59
, pp. 483-489
-
-
Dameron, K.M.1
Volpert, O.V.2
Tainsky, M.A.3
Bouck, N.4
-
118
-
-
0036138149
-
Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis
-
Gautam A, Densmore CL, Melton S, Golunski E, Waldrep JC. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002; 9(1): 28-36.
-
(2002)
Cancer Gene Ther
, vol.9
, Issue.1
, pp. 28-36
-
-
Gautam, A.1
Densmore, C.L.2
Melton, S.3
Golunski, E.4
Waldrep, J.C.5
-
119
-
-
38949145780
-
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
-
Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, Laforme AM, Chaponis DM, Folkman J, Kieran MW. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 2008; 105(3): 985-990.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.3
, pp. 985-990
-
-
Panigrahy, D.1
Kaipainen, A.2
Huang, S.3
Butterfield, C.E.4
Barnes, C.M.5
Fannon, M.6
Laforme, A.M.7
Chaponis, D.M.8
Folkman, J.9
Kieran, M.W.10
-
120
-
-
34447120138
-
Inhibition of trichostatin A-induced antiangiogenesis by small-interfering RNA for thrombospondin-1
-
Kang JH, Kim SA, Chang SY, Hong S, Hong KJ. Inhibition of trichostatin A-induced antiangiogenesis by small-interfering RNA for thrombospondin-1. Exp Mol Med 2007; 39(3): 402-411.
-
(2007)
Exp Mol Med
, vol.39
, Issue.3
, pp. 402-411
-
-
Kang, J.H.1
Kim, S.A.2
Chang, S.Y.3
Hong, S.4
Hong, K.J.5
-
121
-
-
0026469889
-
Induction of thrombospondin 1 by retinoic acid is important during differentiation of neuroblastoma cells
-
Castle VP, Ou X, O'Shea S, Dixit VM. Induction of thrombospondin 1 by retinoic acid is important during differentiation of neuroblastoma cells. J Clin Invest 1992; 90(5): 1857-1863.
-
(1992)
J Clin Invest
, vol.90
, Issue.5
, pp. 1857-1863
-
-
Castle, V.P.1
Ou, X.2
O'Shea, S.3
Dixit, V.M.4
-
122
-
-
33644990380
-
Angiostatic activity of DNA methyltransferase inhibitors
-
Hellebrekers DM, Jair KW, Vire E, Eguchi S, Hoebers NT, Fraga MF, Esteller M, Fuks F, Baylin SB, van Engeland M, Griffioen AW. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006; 5(2): 467-475.
-
(2006)
Mol Cancer Ther
, vol.5
, Issue.2
, pp. 467-475
-
-
Hellebrekers, D.M.1
Jair, K.W.2
Vire, E.3
Eguchi, S.4
Hoebers, N.T.5
Fraga, M.F.6
Esteller, M.7
Fuks, F.8
Baylin, S.B.9
van Engeland, M.10
Griffioen, A.W.11
-
123
-
-
52949090784
-
Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis
-
Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, Iruela-Arispe ML, Merkenschlager M, Sessa WC. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A 2008; 105(37): 14082-14087.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.37
, pp. 14082-14087
-
-
Suarez, Y.1
Fernandez-hernando, C.2
Yu, J.3
Gerber, S.A.4
Harrison, K.D.5
Pober, J.S.6
Iruela-arispe, M.L.7
Merkenschlager, M.8
Sessa, W.C.9
-
124
-
-
33748302836
-
Augmentation of tumor angiogenesis by a Mycactivated microRNA cluster
-
Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Mycactivated microRNA cluster. Nat Genet 2006; 38(9): 1060-1065.
-
(2006)
Nat Genet
, vol.38
, Issue.9
, pp. 1060-1065
-
-
Dews, M.1
Homayouni, A.2
Yu, D.3
Murphy, D.4
Sevignani, C.5
Wentzel, E.6
Furth, E.E.7
Lee, W.M.8
Enders, G.H.9
Mendell, J.T.10
Thomas-tikhonenko, A.11
-
125
-
-
50649105970
-
Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells
-
Zhao HY, Ooyama A, Yamamoto M, Ikeda R, Haraguchi M, Tabata S, Furukawa T, Che XF, Iwashita K, Oka T, Fukushima M, Nakagawa M, Ono M, Kuwano M, Akiyama S. Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. Cancer Lett 2008; 270(1): 156-163.
-
(2008)
Cancer Lett
, vol.270
, Issue.1
, pp. 156-163
-
-
Zhao, H.Y.1
Ooyama, A.2
Yamamoto, M.3
Ikeda, R.4
Haraguchi, M.5
Tabata, S.6
Furukawa, T.7
Che, X.F.8
Iwashita, K.9
Oka, T.10
Fukushima, M.11
Nakagawa, M.12
Ono, M.13
Kuwano, M.14
Akiyama, S.15
-
126
-
-
0032893659
-
Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions
-
Taraboletti G, Benelli R, Borsotti P, Rusnati M, Presta M, Giavazzi R, Ruco L, Albini A. Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. J Pathol 1999; 188(1): 76-81.
-
(1999)
J Pathol
, vol.188
, Issue.1
, pp. 76-81
-
-
Taraboletti, G.1
Benelli, R.2
Borsotti, P.3
Rusnati, M.4
Presta, M.5
Giavazzi, R.6
Ruco, L.7
Albini, A.8
-
127
-
-
34249696957
-
Identification of cellular genes targeted by KSHV-encoded microRNAs
-
Samols MA, Skalsky RL, Maldonado AM, Riva A, Lopez MC, Baker HV, Renne R. Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog 2007; 3(5): e65.
-
(2007)
PLoS Pathog
, vol.3
, Issue.5
-
-
Samols, M.A.1
Skalsky, R.L.2
Maldonado, A.M.3
Riva, A.4
Lopez, M.C.5
Baker, H.V.6
Renne, R.7
-
128
-
-
0242331613
-
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
-
Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003; 100(22): 12917-12922.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, Issue.22
, pp. 12917-12922
-
-
Bocci, G.1
Francia, G.2
Man, S.3
Lawler, J.4
Kerbel, R.S.5
-
129
-
-
1642368865
-
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression
-
Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004; 64(5): 1570-1574.
-
(2004)
Cancer Res
, vol.64
, Issue.5
, pp. 1570-1574
-
-
Hamano, Y.1
Sugimoto, H.2
Soubasakos, M.A.3
Kieran, M.4
Olsen, B.R.5
Lawler, J.6
Sudhakar, A.7
Kalluri, R.8
-
130
-
-
33744503923
-
The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin
-
Damber JE, Vallbo C, Albertsson P, Lennernas B, Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006; 58(3): 354-360.
-
(2006)
Cancer Chemother Pharmacol
, vol.58
, Issue.3
, pp. 354-360
-
-
Damber, J.E.1
Vallbo, C.2
Albertsson, P.3
Lennernas, B.4
Norrby, K.5
-
131
-
-
43649083332
-
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
-
Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008; 98(10): 1619-1629.
-
(2008)
Br J Cancer
, vol.98
, Issue.10
, pp. 1619-1629
-
-
Bocci, G.1
Falcone, A.2
Fioravanti, A.3
Orlandi, P.4
Paolo, A.D.5
Fanelli, G.6
Viacava, P.7
Naccarato, A.G.8
Kerbel, R.S.9
Danesi, R.10
Tacca, M.D.11
Allegrini, G.12
-
132
-
-
42149186928
-
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
-
Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paolo A, Kerbel RS, Danesi R, Del Tacca M, Bocci G. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008; 98(8): 1312-1319.
-
(2008)
Br J Cancer
, vol.98
, Issue.8
, pp. 1312-1319
-
-
Allegrini, G.1
Falcone, A.2
Fioravanti, A.3
Barletta, M.T.4
Orlandi, P.5
Loupakis, F.6
Cerri, E.7
Masi, G.8
Paolo, A.D.9
Kerbel, R.S.10
Danesi, R.11
Tacca, M.D.12
Bocci, G.13
-
133
-
-
34147211504
-
Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment
-
Rico MC, Castaneda JL, Manns JM, Uknis AB, Sainz IM, Safadi FF, Popoff SN, Dela Cadena RA. Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment. J Cell Physiol 2007; 211(2): 504-512.
-
(2007)
J Cell Physiol
, vol.211
, Issue.2
, pp. 504-512
-
-
Rico, M.C.1
Castaneda, J.L.2
Manns, J.M.3
Uknis, A.B.4
Sainz, I.M.5
Safadi, F.F.6
Popoff, S.N.7
Dela Cadena, R.A.8
-
134
-
-
38649125117
-
Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease
-
Punekar S, Zak S, Kalter VG, Dobransky L, Punekar I, Lawler JW, Gutierrez LS. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 2008; 75(1): 9-21.
-
(2008)
Pathobiology
, vol.75
, Issue.1
, pp. 9-21
-
-
Punekar, S.1
Zak, S.2
Kalter, V.G.3
Dobransky, L.4
Punekar, I.5
Lawler, J.W.6
Gutierrez, L.S.7
-
135
-
-
38549105445
-
Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis
-
Thaunat O, Louedec L, Graff-Dubois S, Dai J, Groyer E, Yacoub-Youssef H, Mandet C, Bruneval P, Kaveri S, Caligiuri G, Germain S, Michel JB, Nicoletti A. Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis. Transplantation 2008; 85(2): 281-289.
-
(2008)
Transplantation
, vol.85
, Issue.2
, pp. 281-289
-
-
Thaunat, O.1
Louedec, L.2
Graff-dubois, S.3
Dai, J.4
Groyer, E.5
Yacoub-youssef, H.6
Mandet, C.7
Bruneval, P.8
Kaveri, S.9
Caligiuri, G.10
Germain, S.11
Michel, J.B.12
Nicoletti, A.13
-
136
-
-
0026006134
-
Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma
-
Castle V, Varani J, Fligiel S, Prochownik EV, Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 1991; 87(6): 1883-1888.
-
(1991)
J Clin Invest
, vol.87
, Issue.6
, pp. 1883-1888
-
-
Castle, V.1
Varani, J.2
Fligiel, S.3
Prochownik, E.V.4
Dixit, V.5
-
137
-
-
0023522649
-
Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains
-
Taraboletti G, Roberts DD, Liotta LA. Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J Cell Biol 1987; 105(5): 2409-2415.
-
(1987)
J Cell Biol
, vol.105
, Issue.5
, pp. 2409-2415
-
-
Taraboletti, G.1
Roberts, D.D.2
Liotta, L.A.3
-
138
-
-
19944432454
-
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
-
Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7(1): 101-111.
-
(2005)
Cancer Cell
, vol.7
, Issue.1
, pp. 101-111
-
-
Shaked, Y.1
Bertolini, F.2
Man, S.3
Rogers, M.S.4
Cervi, D.5
Foutz, T.6
Rawn, K.7
Voskas, D.8
Dumont, D.J.9
Ben-david, Y.10
Lawler, J.11
Henkin, J.12
Huber, J.13
Hicklin, D.J.14
D'Amato, R.J.15
Kerbel, R.S.16
-
139
-
-
57649139197
-
A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer
-
Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M, Stopeck AT. A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 2008; 113(12): 3420-3429.
-
(2008)
Cancer
, vol.113
, Issue.12
, pp. 3420-3429
-
-
Gordon, M.S.1
Mendelson, D.2
Carr, R.3
Knight, R.A.4
Humerickhouse, R.A.5
Iannone, M.6
Stopeck, A.T.7
-
140
-
-
1442359994
-
Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice
-
Allegrini G, Goulette FA, Darnowski JW, Calabresi P. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 2004; 53(3): 261-266.
-
(2004)
Cancer Chemother Pharmacol
, vol.53
, Issue.3
, pp. 261-266
-
-
Allegrini, G.1
Goulette, F.A.2
Darnowski, J.W.3
Calabresi, P.4
-
141
-
-
33746542655
-
Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes
-
Lih CJ, Wei W, Cohen SN. Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 2006; 20(15): 2082-2095.
-
(2006)
Genes Dev
, vol.20
, Issue.15
, pp. 2082-2095
-
-
Lih, C.J.1
Wei, W.2
Cohen, S.N.3
-
142
-
-
42249115327
-
Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels
-
Brostjan C, Gebhardt K, Gruenberger B, Steinrueck V, Zommer H, Freudenthaler H, Roka S, Gruenberger T. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res 2008; 14(7): 2065-2074.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.7
, pp. 2065-2074
-
-
Brostjan, C.1
Gebhardt, K.2
Gruenberger, B.3
Steinrueck, V.4
Zommer, H.5
Freudenthaler, H.6
Roka, S.7
Gruenberger, T.8
-
143
-
-
37849035249
-
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia
-
Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26(1): 76-82.
-
(2008)
J Clin Oncol
, vol.26
, Issue.1
, pp. 76-82
-
-
Garcia, A.A.1
Hirte, H.2
Fleming, G.3
Yang, D.4
Tsao-wei, D.D.5
Roman, L.6
Groshen, S.7
Swenson, S.8
Markland, F.9
Gandara, D.10
Scudder, S.11
Morgan, R.12
Chen, H.13
Lenz, H.J.14
Oza, A.M.15
-
144
-
-
6344235259
-
Peroxisome proliferatoractivated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510
-
Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH, Henkin J, Schneider A, Bouck N, Volpert OV. Peroxisome proliferatoractivated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2004; 2(10): 541-550.
-
(2004)
Mol Cancer Res
, vol.2
, Issue.10
, pp. 541-550
-
-
Huang, H.1
Campbell, S.C.2
Bedford, D.F.3
Nelius, T.4
Veliceasa, D.5
Shroff, E.H.6
Henkin, J.7
Schneider, A.8
Bouck, N.9
Volpert, O.V.10
-
145
-
-
0041672462
-
Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts
-
Rofstad EK, Henriksen K, Galappathi K, Mathiesen B. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res 2003; 63(14): 4055-4061.
-
(2003)
Cancer Res
, vol.63
, Issue.14
, pp. 4055-4061
-
-
Rofstad, E.K.1
Henriksen, K.2
Galappathi, K.3
Mathiesen, B.4
-
146
-
-
53149130570
-
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury
-
Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, DeGraff WG, Tsokos M, Wink DA, Roberts DD. Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol 2008; 173(4): 1100-1112.
-
(2008)
Am J Pathol
, vol.173
, Issue.4
, pp. 1100-1112
-
-
Isenberg, J.S.1
Maxhimer, J.B.2
Hyodo, F.3
Pendrak, M.L.4
Ridnour, L.A.5
DeGraff, W.G.6
Tsokos, M.7
Wink, D.A.8
Roberts, D.D.9
-
147
-
-
0036098362
-
Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage
-
Yano K, Oura H, Detmar M. Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage. J Invest Dermatol 2002; 118(5): 800-805.
-
(2002)
J Invest Dermatol
, vol.118
, Issue.5
, pp. 800-805
-
-
Yano, K.1
Oura, H.2
Detmar, M.3
-
148
-
-
25144508039
-
Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis
-
Sutton CD, O'Byrne K, Goddard JC, Marshall LJ, Jones L, Garcea G, Dennison AR, Poston G, Lloyd DM, Berry DP. Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clin Cancer Res 2005; 11(18): 6567-6573.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.18
, pp. 6567-6573
-
-
Sutton, C.D.1
O'Byrne, K.2
Goddard, J.C.3
Marshall, L.J.4
Jones, L.5
Garcea, G.6
Dennison, A.R.7
Poston, G.8
Lloyd, D.M.9
Berry, D.P.10
-
149
-
-
47949099628
-
Modes of resistance to antiangiogenic therapy
-
Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8(8): 592-603.
-
(2008)
Nat Rev Cancer
, vol.8
, Issue.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
150
-
-
0034993498
-
In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects
-
Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clezardin P, Bouck N, Cabon F. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 2001; 15(11): 1373-1382.
-
(2001)
Genes Dev
, vol.15
, Issue.11
, pp. 1373-1382
-
-
Filleur, S.1
Volpert, O.V.2
Degeorges, A.3
Voland, C.4
Reiher, F.5
Clezardin, P.6
Bouck, N.7
Cabon, F.8
-
151
-
-
23244462950
-
Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo
-
Fontana A, Filleur S, Guglielmi J, Frappart L, Bruno-Bossio G, Boissier S, Cabon F, Clezardin P. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer 2005; 116(5): 686-691.
-
(2005)
Int J Cancer
, vol.116
, Issue.5
, pp. 686-691
-
-
Fontana, A.1
Filleur, S.2
Guglielmi, J.3
Frappart, L.4
Bruno-bossio, G.5
Boissier, S.6
Cabon, F.7
Clezardin, P.8
-
152
-
-
53149129492
-
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis
-
Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, Martial JA, DeClerck YA. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008; 14(4): 324-334.
-
(2008)
Cancer Cell
, vol.14
, Issue.4
, pp. 324-334
-
-
Bajou, K.1
Peng, H.2
Laug, W.E.3
Maillard, C.4
Noel, A.5
Foidart, J.M.6
Martial, J.A.7
DeClerck, Y.A.8
-
153
-
-
53149086261
-
Capillary sprout endothelial cells exhibit a CD36 low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling
-
Anderson CR, Hastings NE, Blackman BR, Price RJ. Capillary sprout endothelial cells exhibit a CD36 low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling. Am J Pathol 2008; 173(4): 1220-1228.
-
(2008)
Am J Pathol
, vol.173
, Issue.4
, pp. 1220-1228
-
-
Anderson, C.R.1
Hastings, N.E.2
Blackman, B.R.3
Price, R.J.4
-
154
-
-
0035171206
-
Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1
-
Simantov R, Febbraio M, Crombie R, Asch AS, Nachman RL, Silverstein RL. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest 2001; 107(1): 45-52.
-
(2001)
J Clin Invest
, vol.107
, Issue.1
, pp. 45-52
-
-
Simantov, R.1
Febbraio, M.2
Crombie, R.3
Asch, A.S.4
Nachman, R.L.5
Silverstein, R.L.6
|